Here are 1-3 brief analogies for Bioage Labs (BIOA):

• Bioage Labs is like a company developing 'booster packs' for highly successful obesity drugs such as Wegovy and Zepbound, aiming to significantly enhance their weight loss and muscle benefits by targeting the biology of aging.
• Imagine Bioage Labs as a 'performance tuner' for blockbuster weight-loss medications from companies like Eli Lilly and Novo Nordisk, focused on dramatically improving their results through novel insights into aging biology.

• Azelaprag: An orally available small molecule drug candidate primarily being developed to enhance weight loss in combination with GLP-1R agonists for obesity, and also for improving insulin sensitivity.
• NLRP3 Inhibitors: A class of orally available small molecule brain-penetrant drug candidates in preclinical development for the treatment of diseases driven by neuroinflammation.

Bioage Labs (BIOA) is a clinical-stage biopharmaceutical company focused on the research and development of therapeutic product candidates. As such, the company is currently in the development and clinical trial phase for its drug candidates (e.g., Azelaprag, NLRP3 inhibitors) and has not yet commercialized any products. Therefore, Bioage Labs does not currently have major customers in the traditional sense of selling goods or services.

Eli Lilly and Company (LLY)

Novo Nordisk (NVO)

Kristen Fortney, Co-Founder, Chief Executive Officer, President, and Director

Kristen Fortney co-founded BioAge Labs in April 2015. She holds a Ph.D. in Medical Biophysics from the University of Toronto and completed postdoctoral training at Stanford University as an Ellison/AFAR fellow. Her expertise lies in aging research, systems biology, and bioinformatics, with over a decade of experience in developing bioinformatics approaches for data-driven investigations into aging and age-related diseases. She also serves as an advisor to multiple biotechnology companies. BioAge Labs is described as a venture-backed computational biology startup.

Dov Goldstein, Chief Financial Officer

Dov Goldstein joined BioAge as Chief Financial Officer in November 2021, bringing extensive experience in finance and healthcare. He previously served as Chief Financial and Business Officer at Indapta Therapeutics (2020-2021), CEO at RIGImmune (2018-2020), and CFO of Schrödinger (2017-2018). Notably, he served as CFO of Vicuron Pharmaceuticals from 2000 to 2005, which was acquired by Pfizer for $1.9 billion in 2005. He was also CFO of Loxo Oncology from 2014 to 2015, a company later acquired by Eli Lilly for $8 billion. During his tenure at Vicuron Pharmaceuticals, he raised over $250 million in equity financing. He was also a Managing Partner at Aisling Capital, indicating a pattern of involvement with companies backed by private equity firms. Dov Goldstein holds an M.D. from Yale School of Medicine, an M.B.A. from Columbia Business School, and a B.S. in Biological Sciences from Stanford University.

Eric Morgen, Co-Founder, Chief Operating Officer and Director

Eric Morgen co-founded BioAge Labs with Kristen Fortney in 2015. Prior to BioAge, he was on the faculty at the University of Toronto, where his research focused on biomarker discovery and characterization in high-dimensional datasets from human cohorts. He also possesses a strong background in machine learning.

Paul Rubin, Chief Medical Officer & EVP, Research

Paul Rubin has over 35 years of experience in the biotechnology industry, having led 12 compounds to U.S. approval, including Lunesta® and Xopenex®, with five of these led from discovery through approval. He previously held roles as Executive Vice President Research and Development at miRagen Therapeutics, Inc., Chief Medical Officer at XOMA Corporation, and Executive Vice President Research and Development at Sepracor, Inc.

Peng Leong, Chief Business Officer & Therapeutic Area Head, Brain Aging

Peng Leong is responsible for identifying and executing strategic transactions at BioAge, playing a key role in building the company's pipeline through actions such as in-licensing Azelaprag from Amgen and establishing research collaborations with Lilly and Novartis. His prior experience includes serving as Chief Business Officer of Kazia Therapeutics, where he managed strategy and business development and in-licensed paxalisib. He has been involved in the acquisition or sale of over US$1 billion in pharmaceutical product rights through various roles, including at Merck KGaA and DRI Healthcare. Earlier in his career, he worked in healthcare investment banking at CIBC World Markets and Piper Jaffray, where he contributed to raising over US$1.4 billion for more than 20 biotechnology companies. Peng Leong holds a Ph.D. in Biochemistry from the University of Toronto and an MBA from the University of California, Berkeley.

1. Risk of Clinical Trial Failure or Unpredictability of Later-Stage Results: Bioage Labs explicitly states that "While the results of these preclinical studies and early clinical trials have demonstrated the potential use of azelaprag for the treatment of metabolic disease, they may not be predictive of the results of later-stage clinical trials." The company's lead product candidate, Azelaprag, is currently in or planning Phase 2 clinical trials, including the STRIDES trial with tirzepatide, a trial with semaglutide, and an insulin sensitivity proof-of-concept trial. The success of these trials is critical for the product's viability and market success, and there is no guarantee that Azelaprag will perform as well in later stages as it did in early studies. A previous obesity drug candidate faced a halted clinical trial due to safety concerns, resulting in a significant stock drop and investor lawsuits. Failure to achieve positive outcomes in these later-stage trials would severely impact the company's prospects.
2. Market Competition and Adoption Risk in the Metabolic Disease Landscape: Bioage Labs is targeting the highly competitive metabolic disease market, particularly obesity. This market is currently dominated by well-established glucagon-like-peptide-1 receptor (GLP-1R) agonists such as Zepbound® (tirzepatide) from Eli Lilly and Company, and Wegovy® (semaglutide) from Novo Nordisk. Bioage's strategy involves developing azelaprag as a combination therapy to enhance the effects of GLP-1R agonists. However, the company faces the risk that its combination product may not achieve sufficient differentiation, demonstrate superior efficacy, or gain significant market acceptance against these powerful existing monotherapies or future competing combination therapies.
3. Regulatory Approval Risk: As a clinical-stage biopharmaceutical company, Bioage Labs' product candidates, including Azelaprag and its NLRP3 inhibitors, are subject to rigorous regulatory scrutiny from agencies like the FDA. Even if clinical trials demonstrate positive results, there is no guarantee of regulatory approval. Delays or issues in obtaining necessary approvals could significantly hinder the company's ability to bring its products to market, as highlighted by the statement regarding their NLRP3 inhibitor: "We anticipate submitting an Investigational New Drug application (IND) for an NLRP3 inhibitor in the second half of 2025 and, if cleared, initiating a Phase 1 clinical trial in the first half of 2026."

For Bioage Labs (BIOA), the expected drivers of future revenue growth over the next 2-3 years are primarily centered around the advancement and expansion of its clinical pipeline:

1. Positive Clinical Trial Results for Azelaprag in Combination with GLP-1R Agonists for Obesity: The ongoing STRIDES clinical trial assessing azelaprag with tirzepatide is anticipated to report topline results in the third quarter of 2025. Additionally, the second Phase 2 trial combining azelaprag with semaglutide is expected to initiate in the first half of 2025, with topline results projected in the second half of 2026. Successful outcomes from these trials are critical as they target the substantial and growing global market for GLP-1R agonists, potentially leading to an all-oral combination product for obesity.
2. Expansion of Azelaprag's Indications to Include Insulin Sensitivity: Bioage Labs plans to initiate an insulin sensitivity proof-of-concept trial of azelaprag monotherapy in the first half of 2025, with topline results expected in the second half of 2025. Positive results from this trial would validate azelaprag's potential for indication expansion, opening up another significant market opportunity beyond obesity.
3. Advancement of the NLRP3 Inhibitor Program into Clinical Trials: The company anticipates submitting an Investigational New Drug (IND) application for an orally available, small molecule brain-penetrant NLRP3 inhibitor in the second half of 2025. If cleared, a Phase 1 clinical trial is expected to commence in the first half of 2026. The successful progression of this program into clinical development would diversify Bioage Labs' pipeline and establish a new potential revenue stream in the neuroinflammation therapeutic area.

Share Issuance

• BioAge Labs priced an upsized underwritten public offering of 5,897,435 shares of common stock at $19.50 per share on January 21, 2026, expected to generate approximately $115.0 million in gross proceeds.
• The company granted underwriters a 30-day option to purchase up to an additional 884,615 shares of common stock in connection with the January 2026 offering.
• A registration statement for the resale of up to 2,227,124 shares of common stock by a selling stockholder was filed, from which the company itself would not receive proceeds.

Inbound Investments

• Institutional investors collectively hold a 43% ownership stake in BioAge Labs.
• Private equity firms hold a 20% stake in the company.
• Significant institutional shareholders include AH Capital Management, L.L.C., Sofinnova Investments, and Octagon Capital Advisors LP.

Capital Expenditures

• In the last 12 months, BioAge Labs reported capital expenditures of approximately $633,000.
• Net proceeds from the January 2026 public offering are intended to fund, among other things, capital expenditures.